

# INDEX

- A + B designs, dose-escalation trials, 133–134
- Action menu, 12–13
- Adaptive clinical trial design, *see* Adaptive trial design; Adaptive trial monitoring (ATM)
  - adaptive dose-escalation design, 26
  - biomarker-adaptive design, 26
  - characteristics of, 23–24
  - drop-loser design (DLD), 25
  - group sequential design, 24–25
  - response-adaptive randomization design (RARD), 25–26
  - sample-size reestimation design, 25
  - single-arm trial multistage design, 26
- Adaptive design (AD), *see* Adaptive clinical trial design; Adaptive trial design
  - characteristics of, 1–2
  - validation, 224–226
- Adaptive Design Theory and Implementation Using SAS and R* (Chang), 111
- Adaptive trial design:
  - basics of, 75–77
  - characteristics of, 3, 5–8, 12
  - using classifier biomarker, 93–95
  - drop-loser trial, 90–93
  - monitoring, *see* Adaptive trial monitoring (ATM)
  - oncology, *see* Oncology adaptive trial design
  - play-the-winner trial, 95–102
  - sample-size reestimation, 77–90
  - simulator, *see* Adaptive trial simulator
  - two-stage, 112, 119
- Adaptive trial monitoring (ATM):
  - characteristics of, 1–2, 13
  - conditional power, 109–112
  - error-spending approach, 103–106, 115
  - futility index, 109–112
  - recalculating stopping boundaries, 105, 107–109
  - sample size reestimation, 113–114
  - trial examples, 114–121
  - validation, 226
- Adaptive trial simulator:
  - adjusting critical region method, 149–151
  - classical design with multiple treatment groups, 165
  - classical design with two parallel treatment groups, 151–157
  - dose-escalation design, oncology trial, 168–171
  - dropping losers, 151, 155–156, 166–168
  - early stopping, 162–165
  - flexible design, with sample-size reestimation, 157–159
  - group sequential design, with one interim analysis, 161–162
  - multigroup trial, with response-adaptive randomization, 165–166
  - random-play-the-winner randomization, 160–161
  - sample-size reestimation, 157–159, 162–165
- Adjusting critical region (ACR), 149–151
- Adjustment, 149–151, 156, 159–160, 213
- Adverse drug reaction (ADR), 130
- Adverse effects, types of, 51, 129–130
- Algorithm validation, 216
- Alpha, 5, 82, 87, 91, 97, 102, 124, 158
- Analysis of variance (ANOVA), 41–43, 173, 188–189, 197, 201, 209–210, 212, 218–220, 235, 238–239
- ANOVA, *see* Analysis of variance (ANOVA)
- Arctan transformation, 190–191, 204–205, 218, 235

- Area under the curve (AUC), 22, 38, 132  
Assumption, 27
- Balanced design, 18
- Bayesian approach:  
  characteristics of, 2, 63, 77, 151  
  continual reassessment method (CRM),  
    134–135, 147, 228  
  dose-escalation design, 168
- Bernoulli:  
  confounding variable, 204, 220, 237  
  distribution, 172, 177, 229
- Beta distribution, 172, 177, 229
- Bias, operational, 24
- Binomial distribution, 33, 172–173, 177, 185,  
  189, 195, 220, 229–230, 235
- BIO Adaptive Design Working Group, 23
- Bioavailability design, 21–22
- Bioequivalence:  
  design, 14, 21–23  
  test, 36–38  
  trial, 16–17, 39
- Biomarker-adaptive design, 2
- Biomarker-negative population (BNP),  
  94
- Biomarker-positive population (BPP), 94
- Biomarkers, classified, 93–95
- Bivariate *t*-distribution, 238
- Bloch-Kraemer intraclass  $\kappa$  coefficient, 190,  
  219, 236
- Block design, 210, 220, 239
- Bonferroni adjustment, 213
- Boundary/boundaries, *see* Lower bound;  
  Upper bound  
  adaptive trial design, 7  
  crossing probabilities, 224  
  parameter, 72  
  scales, 52
- Carryover effects, 20–21
- Case-control studies, 209, 219, 238
- Cauchy distribution, 173, 177, 229
- Censoring, 49
- Center for Drug Evaluation and Research  
  (CDER), 22
- Chi-square, generally:  
  distribution, 173, 177, 185, 229–230  
  test, 31–32, 41–42, 189–190, 201, 219, 235,  
    239
- Classical clinical trial design, *see* Classical  
  trial design  
  confirmatory trials, 15  
  crossover design, 17–18  
  dose-response relationship, 17  
  endpoints, 15  
  exploratory trials, 16  
  factorial design, 18  
  multicenter trials, 16  
  nonequivalence trials, 16–17  
  noninferiority trials, 16–17  
  parallel design, 17  
  substantial evidence, 15  
  superiority trials, 16
- Classical design, *see* Classical clinical trial  
  design; Classical trial design  
  adaptive trial simulator, 151–157, 165  
  large-sample-size calculation, 43–44  
  multigroup trial design, 209–213  
  reference, 187–213  
  sample-size calculation methods,  
    235–239  
  single-group design, 187–196  
  two-group design, 196–209  
  validation of, 217–220
- Classical trial design:  
  characteristics of, 1–5, 12  
  hypothesis test, 27–28  
  mathematical notes, 43–50  
  sample-size calculation, 28–43  
  under- or overpowered designs, 29–30
- Clinical trial design:  
  adaptive, 23–26  
  classical, 14–18  
  requirements of, 14  
  selection of, 18–23
- Clinical trials, *see specific types of clinical  
  trials*  
  Phase I, 123, 129  
  Phase II, 25, 90, 123–124, 144–145, 151  
  Phase III, 25, 78–79, 81–84, 86, 90, 111,  
    149
- Cluster randomization, 198, 220, 237
- Cochran-Armitage test, 43, 201, 210–211,  
  219, 239
- Comparative bioavailability study, 21
- Complete crossover design, 19
- Compute, 9–10, 12, 30–31, 35–43, 55, 57,  
  64–65, 124, 126, 136–137, 139, 185–186
- Computer programs, validations, 231–234.  
  *See also* MS Word; Software;  
  Spreadsheets
- Conditional power:  
  adaptive trial monitoring, 119  
  calculation of, 112–113, 118  
  implications of, 1, 7, 63–64, 77–78, 81, 83,  
    86, 92, 109–111, 226  
  sequential trial design, 73–74  
  trial examples, 117

- Conditional probability, 29, 63, 72–73
- Confidence interval (CI):  
 calculator, 3, 13, 182, 185–186  
 impact of, 22–23, 39, 46–48, 72, 162–163, 193–196, 208, 212–213, 218–219, 220, 229–230, 236, 238–239
- Confirmatory trial, 15
- Continual reassessment method (CRM):  
 characteristics of, 2, 26  
 design simulation, 138–140  
 dose-escalation trial design, 133–135, 141–143  
 mathematical notes, 146–148  
 validation, 228, 232–234
- Continuity correction, 209
- Contrast test, 220
- Copy, 4–5, 11
- Correlation coefficient, 191–192, 196–197, 204–205, 236, 238
- Crossover design:  
 characteristics of, 17–21, 29, 197–198, 220, 237–238  
 $p \times q$ , 19  
 $2 \times 2$ , 17, 71, 197–198, 218, 220, 237
- CTriSoft, 12. *See also* Software, CTriSoft
- Cumulative error rates, 106
- Cut, 11
- Data analyses, adaptive trial designs, 23–24.  
*See also* Interim analysis
- Data monitoring committee (DMC), 62
- Decision making, influential factors, 94
- Decision rules, 55, 145
- Decision tree, 143–144
- Degrees of freedom, 173, 188–189, 191–192, 201, 211
- Density function, 48. *See also* Probability density function
- Design menu, 11–12
- Distribution calculator, 3, 230
- Donner's method, 198, 220, 237
- Dose-escalation algorithm, 133–134
- Dose-escalation design (DED), *see* Dose-escalation trial design  
 characteristics of, 1, 10–11  
 oncology trial, 168–171  
 validation of, 228
- Dose-escalation rule, 132
- Dose-escalation trial design, 3, 10–12, 21, 77.  
*See also* Dose-escalation trial monitoring (DTM)
- Dose-escalation trial monitoring (DTM):  
 characteristics of, 1–2  
 using CRM, 141–143, 168
- Dose-limiting toxicity (DLT), 129–133, 135–138, 140, 142–143, 228
- Dose range, dose-escalation trial design, 131–132
- Dose-response:  
 probability model, 146–147  
 relationship, significance of, 138  
 trials, 17–18, 25, 42–44
- Dose-toxicity modeling, 130–131, 147–148
- Double exponential distribution, 174
- Drop-loser design (DLD):  
 characteristics of, 93, 151, 155–156, 166–168  
 defined, 25  
 mechanism, 90  
 seamless design, 90–93
- Dropouts, 21, 48
- Drug approval, substantial evidence, 15
- Early stopping, 24–25, 52–53, 56–62, 123–128, 155, 158, 161–165
- Edit menu, 11
- Effect-size ratio, 78
- Efficacy:  
 boundary, 117  
 early stopping, 54–56  
 stopping, 162–163  
 stopping probabilities (ESP), 111–112, 120
- Ending dose, 133
- Endpoint(s):  
 adaptive trial design, 78, 97  
 clinical trial, 15, 24  
 classical trial design, 42–43  
 group sequential trial design, 66  
 implications of, 91  
 panel, 5  
 primary, 15, 86–90  
 secondary, 15  
 survival, 58–60, 65, 68, 120–121, 223–224
- Enrollment rate, 48–50
- Equivalence:  
 design, 22–23  
 tests, 38–39, 193, 205–208, 219–220, 236, 238  
 trial, 16–17, 23
- Error inflation, 51–52, 119. *See also* Type I error(s); Type II error(s)
- Error-spending approach, 103–106, 115, 224
- Escalation design validation, 3 + 3, 228, 231–232
- Escalation probability, 134
- Escalation rules:  
 customization of, 140–141  
 types of, 1–2, 21

- Estimators, bias-adjusted, 74
- Example, defined, 12. *See also specific types of designs and trials*
- ExpDesign Studio (ExpDesign):  
 characteristics of, 1–2  
 defined, 1  
 icons, 2–3  
 integrated environment, 2
- Exploratory trials, 15–16
- Exponential distribution, 48–49, 173, 177, 185, 229–230. *See also* Exponential survival distribution
- Exponential survival distribution, 32–33, 46, 50, 68, 84, 202–204, 212, 218, 220, 237
- External validity, 23
- Factorial designs, 18
- Family-wise error (FWE), 160, 165
- F-distribution, 173, 177, 185, 198, 209–210, 229–230
- Fibonacci number, 132
- File menu, 11
- Finite population, 188, 190, 193–195, 218, 235–236
- Fisher's arctan transformation, 190, 204–205, 218, 235, 238
- Fisher's exact test, 199–200, 220, 237
- Fisher's LSD method, 212
- Flexible design, with sample-size reestimation, 157–159
- Food, Drug and Cosmetics Act, Kefauver-Harris amendments, 15
- Four-stage sequential design, 223
- Futility:  
 binding, 225  
 characteristics of, 24–25, 53, 76, 80–81, 83–84, 86, 88, 92, 123–128, 158  
 early stopping, group sequential trial design, 56–58  
 index, 63–64, 66, 73, 109–112  
 rules, 150–151  
 stopping, 162–163
- Gamma distribution, 151, 174, 177, 185, 229–230
- Gaussian distribution, 177, 229
- Genetic technologies, 93
- Genomics, 93
- Geometric distribution, 174, 177, 229
- Gompertz distribution, 174
- Goodness of fit, 201
- Graphic calculator, 3, 13, 150, 182–184
- Graphic user interface (GUI), 217
- Group sequential design, *see* Group sequential trial design  
 adaptive trial simulator, 161–162  
 classical, 118  
 sequential design guidelines, 53–62  
 traditional, 105  
 validation, 221–224
- Group sequential test, 51
- Group sequential trial design:  
 basics of, 51–53  
 characteristics of, 4–6, 24–25  
 mathematical notes, 68–74  
 monitoring, 62–68
- Hazard rate, 46–47, 50, 85, 208
- Hazard ratio, 46–48, 65, 71, 120, 213
- Help menus, 13
- Hypergeometric distribution, 201
- Hyperlogistic model, 168–170
- Hypotheses panel, 5, 82
- Hypothesis tests, 27–28, 31–32, 35, 54, , 235–238
- Hypothesis testing, 29, 41
- ICH, trial design guidelines, 14
- Individual bioequivalence, 22
- Inferential statistics, 175
- Information time, 7
- Integrity, 24
- Interim analysis (IA):  
 adaptive trial monitoring, 107–110, 120  
 characteristics of, 24–25, 51, 54, 64, 103, 128, 161–162  
 number and timing changes, 114–119
- Internal validity, 24
- In vivo studies, bioequivalence trials, 22
- Kendall's test for independence, 192, 235
- Lan-DeMets power family, 226
- Laplace distribution, 174, 177, 229
- Latin square design, 210–211, 238
- Lethal dose (LD), 131–132
- Likelihood function, 147
- Linear regression, 191–192, 196, 205, 219, 236, 238
- Log-hazard ratio, 47, 65, 71
- Logistic distribution, 174–175
- Logistic model, 200
- Logistic regression, 130, 191, 219, 236
- Logit model, 130–131, 137, 209
- Lognormal data, 37–38, 220
- Lognormal distribution, 175, 177, 229

- Log-rank test, 33, 45, 68, 71, 203–204, 219, 237
- Lower bound, 150, 162–163, 166
- McNemar's test, 35, 189, 218, 235
- Mann-Whitney U test, 196–197, 200, 218, 237
- Mantel-Haenszel test, 39–40, 201, 219, 237
- Matched-pairs parallel design, 19
- Maximum efficacy dose, 21
- Maximum likelihood estimate, 46
- Maximum tolerable dose (MTD), 1, 21, 26, 129–143, 148, 168, 228
- Maximum utility model, *see* MaxUtility
- MaxUtility, 1, 124, 126, 128, 151, 170
- Mean, 36, 38–39, 43–44, 54–56, 69–70, 91, 102, 161–162, 164–167, 205–211, 218–220, 235–238
- Mean survival time, 46
- Menus, types of, 11–13
- Microarray analysis, 198, 213, 220, 239
- MinExp, 1
- MinExpSize, 124–127, 227
- Minimal effective dose level (MELD), 132
- Minimum effective dose, 220, 239
- MinMax, 1, 227
- MinMaxSize, 124–125, 227
- MINP, 75–76, 103, 110–111, 114
- MPP, 75–76, 82–84, 92, 103, 110–111, 114
- MSP, 75–76, 78, 80–81, 103, 110–113, 225
- MS Word, 184
- Multinomial generation, 181–182
- Multicenter trials, 16
- Multicollinearity, 20
- Multigroup trial:
  - adaptive trial simulator, 161–162
  - design, 209–213
- Multiple regression, 20, 192, 219
- Multisample hypothesis tests, 211–213
- Multistage design (MSD), 1. *See also* Multistage trial design
- Multistage trial design:
  - characteristics of, 3, 9–10, 12
  - oncology adaptive trial design, 123–148
  - single-arm, 26
  - validation, 3, 9–10, 12
- Multivariate generation, 179–181
- MyExpDesign Studio.htm, 12
- Noncentrality, 201, 210–212
- Noninferiority design, 86–90. *See also* Noninferiority trial
- Noninferiority tests, 35–36, 205–208, 220, 238
- Noninferiority trial, 16–17, 23
- Normal distribution, 104, 151, 158, 173, 175–177, 179, 181, 185, 229
- Null hypothesis, 23–24, 27, 29, 54–56, 58, 60, 62, 118, 124, 126–128, 146, 166–167
- Number of events, 48–50
- O'Brien boundary, 7, 53, 80, 83, 85, 88, 92
- O'Brien-Fleming boundary, 53, 104–105
- Observed Info, 64
- Observed Stage, 64
- Odds ratio (OR), 39–41, 45–46, 195, 201, 209, 219, 236–237
- Oncology adaptive trial design:
  - dose-escalation, 129–141
  - dose-escalation trial monitoring, using CRM, 141–143
  - mathematical notes, 143–148
  - multistage, 123–128, 143–146
- Oncology drugs, 21
- Oncology trials, 33–34. *See also* Oncology adaptive trial design
- Options menu, 4, 183
- Outlier data, 22
- Overpowered designs, 25, 29–30
- Overshooting, dose-escalation trial design, 137
- Parallel design, 17, 19, 22, 29, 205–206, 219–220, 238
- Pareto distribution, 175–177, 229
- Pascal distribution, 229
- Paste, 5, 184
- Pearson's chi-square test, 31–32, 41, 199–201, 237
- Pharmaceutical(s):
  - alternatives, 21
  - equivalents, 21
- Pharmacokinetically guided dose escalation (PGDE), 132
- Pharmacokinetics, 17, 22, 38
- PhRMA Adaptive Design Group, 23
- Placebo-controlled trials, 16, 18, 29
- Pocock boundary, 7, 53, 64, 80, 83, 85, 88, 92, 105, 221
- Point estimation, 74. *See also* Time-point interactions
- Poisson distribution, 176–177, 185, 229–230
- Pop-up messages, 8
- Population bioequivalence, 22
- Postulation, 27

- Power:  
 characteristics of, 5, 28–30, 82, 91, 124, 164, 221–223  
 conditional, *see* Conditional power  
 predictive, 63, 73–74
- Power-family (PF) error-spending function, 104–105
- Practice guide, xvii–xviii
- Predicted MTD (PMTD), 134
- Predictive biomarker, 94
- Predictive power, 63, 73–74
- Predictive probability, 147
- Print, 4–5, 7–8, 11, 184–186
- Probability:  
 calculator, 13  
 density function, 49, 72  
 distributions, 146–147, 229  
 function, 29, 171–177, 195–196
- Prognostic biomarker, 93–94
- Prophylactic drugs, 20
- Proportion, 5, 44–45, 56–58, 87, 97–98, 124, 195, 199, 201, 207–209, 211–212, 220, 235–239
- Proteomics, 93
- p*-scale, 224
- p*-value:  
 adaptive trial simulator, 158  
 implications of, 53, 56–60, 62, 66, 72, 74, 86, 88, 94  
 stagewise, *see* Stagewise *p*-values  
 trial examples, 119–120
- Randomization:  
 adaptive trial simulator, 166  
 in crossover design, 19  
 dynamic, 2  
 random-play-the-winner, 150, 160–161  
 response-adaptive, 2, 24, 98, 165–166
- Randomized play-the-winner (RPW) model, 26, 95–98, 165–167
- Randomizer, 12, 228–229
- Random multibinomial, 181–182
- Random multivariate, 179–181
- Random number generation, 177
- Random univariate, 177–179
- Rare events, 195–196, 219, 236
- Rayleigh distribution, 176–177, 229
- Recruitment, 19
- Rectangular distribution, 176
- Regression coefficient, 191, 218, 235
- Relative risk, 45
- Repeated confidence interval (RCI), 64, 73–74
- Repeated-measure model, 77
- Report, 3, 5, 8, 10–12, 55–56, 58, 60–62, 81
- Residual effects, 20
- Response-adaptive randomization design (RARD), 25–26, 77, 97, 99–102
- Robustness, 157
- Sample size:  
 adjustment of, 24, 78  
 calculation methods, 15, 18, 28–43, 111, 235–239  
 cumulative, 126–127  
 determination, 23  
 fixed, 24, 77  
 influential factors, 29  
 recalculation, 189  
 reestimation (SSR), 2, 5–7, 25, 77–90, 92, 113–114, 157–159, 162–165, 226  
 required, 2  
 validation, 221
- SAS program, CRM validation, 232–234
- Save, 4–5, 8–11
- Seamless design, 25, 90–93
- Self-study guide, xvii–xviii
- Sequence effects, 22
- Sequential design (SD), defined, 1. *See also*  
 Group sequential trial design;  
 Sequential trial design
- Sequential trial design, 3, 12, 17, 68
- Sign test, 187, 218, 235
- Simulation:  
 adaptive trial design, 7–9, 80, 85–86, 95, 98–100, 102  
 beta version, 217, 228  
 dose-escalation trial design, 135–140
- Single-arm trial multistage design, 26
- Single-stage design:  
 classical, 126  
 group, 187–196  
 dose-escalation design simulation, 136–137
- Software, CTriSoft:  
 corrections, 255  
 improvements to, 255  
 installation, 253  
 license agreement, 253–254  
 updates, 255  
 warranties, 254–255
- Spreadsheet applications, 126
- Stagewise *p*-values:  
 product of (MPP), 75–76, 82–84, 92, 103, 110–111, 114  
 sum of (MSP), 75–76, 78, 80–81, 103, 110–113, 225

- weighted inverse normal (MINP), 75–76, 103, 110–111, 114
- Standard deviation, 29–30, 36–37, 39, 42, 46, 54–55, 69, 94–95, 164–165, 169, 171, 188, 205
- Starting (initial) dose, 131–132
- Startup window, 3–4
- Statement, 27
- Statistical:
  - calculator, 182, 185
  - outcome validation, 216–217
- Statisticians.org, 12
- Status Bar, 11
- Stochastic approximation (SA), 132
- Stopping boundary:
  - adaptive trial monitoring, 103–105, 108
  - calculation of, 107–108
  - implications of, 52–53, 56, 66, 58–60, 75, 77, 80–81, 224–225
  - trial examples, 115–117
  - validation, 226
- Stopping probability, 56–57, 59–60
- Stopping rules, 62, 76, 126–128, 150–151
- Strict TER (STER), 132–133, 140
- Student's *t*-distribution, 176–177, 185, 229–230
- Substantial evidence, 15
- Superiority trials, 16, 23, 87
- Survival:
  - analysis, 203–204, 219
  - characteristics of, 31, 46–48, 207–209, 220, 237–238
  - distributions, 45
- System requirements, 253
  
- t*-distribution, 39, 238. *See also* Student's *t*-distribution
- Theta, 64
- 3 + 3 rules, 132–133
- Three-stage design(s):
  - characteristics of, 123–124
  - dose-escalation example, 145–146
  - optimal, 227
  - sequential, 224
  - testing, 126–128
  - validation, 227, 231
- Time-point interactions, 200, 218, 237
- Time-to-event analysis, 68
- Time to progression (TTP), 84–86
- TipDay, 2
- Tip of the day, 182–183
- Tiptext, 2
- Titration design, 21
- Toolbar, 2–3, 182
  
- Toolkits:
  - types of, 182–186
  - validation of, 229–230
- Tools menu, 13
- Toxicity, 1, 21, 129–133, 136, 138–139, 146–148, 168
- Traditional escalation rules (TERs):
  - characteristics of, 132–133, 135, 228
  - 3 + 3, 21, 140
- Trial Monitor, 64–66
- Trial simulation, validation of, 228
- t*-statistics, 194, 220, 236
- t*-tests, 29–31, 36, 188, 192–193, 196, 205–207, 218, 220, 235, 237–238
- Two one-sided test procedure, 22
- Two-group design, 196–209
- Two-parallel-arm clinical trial, 29
- Two-stage adaptive design, 226
- Two-stage designs, *see specific types of two-stage designs*
- Two-stage dose-escalation design:
  - example of, 144–145
  - simulation, 137–138
- Two-stage escalation algorithms, 1–2
- Two-stage group sequential design, 54–55
- Type I error(s):
  - characteristics of, 23, 52–54, 99, 105, 212–213
  - rate, 23, 27, 103, 119, 123, 126, 143, 145–146, 224, 239
- Type II error(s):
  - characteristics of, 143
  - rate, 27, 146
  
- Unbalanced design, 18
- Unblinded data, 51
- Underpowered designs, 25, 29–30
- Undershooting, dose-escalation trial design, 137–138
- Uniform distribution, 229
- U.S. Food and Drug Administration (FDA):
  - bioequivalence, 22
  - drop-loser trial, 90
  - trial design guidelines, 14–15
- Univariate generation, 177–179
- Upper bound, 150, 162–163
- Utility:
  - index, 126
  - rules, 150
  - stopping, 162–163
- Utility-offset model, 151
  
- Validation, 215–234
- Validity, 23

- View menu, 11–12
- Virtual trial data:
  - random multibinomial generation, 181–182
  - random multivariate generation, 179–181
  - random number generation, 177
  - random univariate generation, 177–179
- Wang-Tsiatis boundary, 53–54, 105, 222–223
- Washout period, 20
- Web site, 12
- Weibull distribution, 177, 185, 229–230
- Whitehead logistic ratio, 218, 237
- Whitehead triangle boundaries, 63
- Wilcoxon rank-sum test, 196–197, 218, 237
- Wilcoxon signed-rank test, 187, 218, 235
- William's test, 220, 239
- Withdrawal, early, 49. *See also* Dropouts
- Word splitter, 3
- z-method, 218
- z-scale, 221–222
- z-statistic, 52, 56–57, 59, 62
- z-test, 197, 237
- z-transformation, 190, 236
- Z-value, 119–120